One visit, a much wider view of your health

Main indicators

Colorectal screening, upper-GI inflammation, reflux-related concerns, polyps, biopsy routing and stool-based risk signals where appropriate.

Screening logic

Digestive screening is useful when it combines direct visual assessment, biopsy routing and provider-led interpretation instead of relying on blood markers alone.

Patient benefit

Endoscopy is actionable: suspicious findings can be biopsied, and suitable polyps may be removed in the same pathway when the provider considers it appropriate.

Evidence base

* In the NordICC randomised trial (Bretthauer et al., NEJM 2022), invitation to screening colonoscopy was associated with about 18% lower colorectal-cancer incidence over 10 years. The primary analysis did not show a significant reduction in colorectal-cancer mortality.

Main indicators

Abdominal, thyroid, carotid or pelvic ultrasound; low-dose chest CT for elevated lung-risk profiles; targeted MRI where provider policy supports it.

Screening logic

Imaging should be selected by age, symptoms, smoking history, family history and provider policy, then interpreted with the rest of the screening record.

Patient benefit

Imaging can identify structural findings that blood tests cannot, then route unclear results to the right specialist instead of leaving the patient with isolated images.

Evidence base

NELSON trial 10-year follow-up (de Koning et al., NEJM 2020): low-dose CT screening reduced lung-cancer mortality by 24% in men and 33% in women among high-risk groups. For MRI: across the most common cancers, stage-I detection delivers 80-95% 5-year survival vs <30% at stage IV (Cancer Research UK, 2023).

Main indicators

Blood pressure, lipids, glucose metabolism, ECG, echocardiography and carotid plaque assessment where selected by risk profile.

Screening logic

Cardiovascular prevention is most useful when blood pressure, lipids, diabetes risk and vascular imaging are interpreted together, not as isolated numbers.

Patient benefit

Creates a clearer cardiovascular risk picture and supports referral to cardiology, medication review or lifestyle intervention when the provider recommends it.

Evidence base

ESC Guidelines (Visseren et al., Eur Heart J 2021) endorse carotid plaque imaging for cardiovascular risk stratification in selected adults. In randomised-trial meta-analyses, each 10 mm Hg reduction in systolic blood pressure was linked to 27% lower stroke risk and 17% lower coronary-heart-disease risk (Lancet 2016); each 1 mmol/L reduction in LDL cholesterol with statin therapy reduced major vascular events by about 21% (Lancet 2012).

Main indicators

Urine testing, kidney-function markers, urinary-tract review, ultrasound and prostate-related discussion for men where age and risk profile make it relevant.

Screening logic

Kidney and urinary markers are often silent. Combining laboratory findings with ultrasound and specialist review helps separate monitoring from action.

Patient benefit

Connects common silent markers, such as kidney function and urinary findings, with same-trip specialist review if the result needs escalation.

Main indicators

HbA1c or glucose, thyroid function, liver and kidney panels, lipid profile, vitamin status and inflammatory markers where suitable.

Screening logic

Early metabolic signals can change prevention strategy before symptoms appear, especially when diabetes, fatty liver, lipids and thyroid function are reviewed together.

Patient benefit

Builds a baseline for long-term health management and helps identify trends that can be followed at home after the China visit.

Main indicators

Provider-selected breast, cervical, prostate, colorectal, lung or upper-GI screening signals, supported by imaging, endoscopy and adjunctive markers where useful.

Screening logic

Cancer screening works best when it is targeted by age, sex, family history and risk profile. Generic tumour-marker panels alone are not enough.

Patient benefit

Keeps screening targeted, with abnormal or unclear findings routed to specialist interpretation rather than self-diagnosis.

Evidence base

Across Western healthcare systems, early-stage detection consistently shows 5- to 8-fold higher 5-year survival compared to late-stage diagnosis (Cancer Research UK, 2023 data; consistent with US SEER data).

Main indicators

Abnormal, borderline or unclear findings that need review by gastroenterology, cardiology, imaging, urology, endocrinology or another relevant department.

Screening logic

Choose tests by age, history and measurable risk, then turn results into a clear next step. Interpretation is what turns testing into a plan.

Patient benefit

The trip ends with priorities: what needs action now, what can be monitored and what should be shared with the home-country clinician.